Fosun Pharma seeks shareholder approval for CEO Liu Yi as executive director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. will hold its 2025 second extraordinary general meeting (EGM) on Tuesday, December 2, 2025, at 1:30 p.m. in Shanghai. The primary agenda is an ordinary resolution for the election of Mr. Liu Yi as an executive director. This appointment follows the resignation of Mr. Wu Yifang as a non-executive director on September 30, 2025, due to a personal work assignment. The board is mandated to consist of twelve directors.

Mr. Liu Yi, currently the company's chief executive officer and president, has been proposed by the board and its nomination committee as a candidate for the tenth session of the board. His term of office, if approved, will commence from the EGM approval date and conclude with the expiration of the tenth session of the board. Mr. Liu will not receive separate remuneration for this executive director appointment.

For H shareholders to attend and vote at the EGM, the register of members for H shares will close from Thursday, November 27, 2025, to Tuesday, December 2, 2025. Transfer documents for H shares must be lodged with Tricor Investor Services Limited by 4:30 p.m. on Wednesday, November 26, 2025. Mr. Liu Yi holds personal interests in 35,444 shares of the company, comprising 15,444 A shares and 20,000 H shares, representing approximately 0.001% of the total shares.